New Data on Rinvatercept at MDA 2026
At the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in March 2026, Keros presented new data from a Phase 1 trial of rinvatercept in healthy volunteers (www.globenewswire.com). The trial showed that rinvatercept was generally well-tolerated with no serious adverse events and produced pharmacological effects consistent with its mechanism (www.globenewswire.com) (www.globenewswire.com). Notably, proteomic analyses confirmed target engagement: serum biomarkers indicated reduced fibrosis and inflammation (via activin inhibition) and shifts in energy metabolism favoring muscle growth (www.globenewswire.com). Treated subjects had increases in lean muscle mass and bone mineral density relative to placebo (www.globenewswire.com). These findings support rinvatercept’s therapeutic rationale – by trapping myostatin/activin, it aims to boost muscle strength, inhibit fibrosis, and improve bone health (www.globenewswire.com). Keros’s CEO highlighted that the data “underscore the wide-ranging therapeutic potential of rinvatercept” and bolster confidence to advance into Phase 2 trials in Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS) (www.globenewswire.com). In addition to the human data, Keros presented preclinical results showing rinvatercept improved muscle and bone outcomes in DMD and ALS mouse models (www.globenewswire.com). These developments position rinvatercept as the core value driver going forward. However, it will face the true test in patient trials – the first Phase 2 in DMD is targeted to begin in Q1 2026 pending regulatory clearance (www.globenewswire.com) (www.globenewswire.com).
Dividend Policy and Capital Returns
Like most early-stage biotechs, Keros has never paid a regular dividend – its forward dividend yield is 0% (uk.finance.yahoo.com). Instead, the company reinvests in R&D and has sustained net losses (e.g. $187 million net loss in 2024) as it develops its pipeline (ir.kerostx.com). There is no recurring AFFO/FFO metric applicable here, since Keros has no operating cash flows or profit to distribute. That said, Keros undertook an extraordinary shareholder return in 2025. After concluding a strategic review, the Board declared $375 million of its cash as “excess capital” to be returned to stockholders (ir.kerostx.com). This culminated in a large share repurchase program: in October 2025 Keros bought out all shares held by two major investors (ADAR1 Capital and Pontifax) for ~$181 million, and by November it completed a tender offer for an additional ~$194 million of stock at $17.75 per share (www.globenewswire.com) (www.biospace.com). In total, Keros repurchased roughly 21.1 million shares (over 50% of shares outstanding) through these transactions (www.biospace.com). This one-time capital return was funded by Keros’s hefty cash reserves, bolstered by a $200 million upfront payment from Takeda for the elritercept license (ir.kerostx.com). Management and an activist investor framed the buybacks as a way to enhance shareholder value and return proceeds from the Takeda deal to investors (www.globenewswire.com). Going forward, Keros has no plans for recurring dividends; any further capital return would likely depend on additional licensing windfalls or strategic decisions. For now, remaining shareholders benefit from a doubled ownership stake in the pipeline per share (due to the halved share count), while the company retains sufficient cash for development needs.
Financial Position, Leverage, and Coverage
Keros emerged from 2025 with a very strong balance sheet and minimal debt. As of Q3 2025, the company held $693.5 million in cash and equivalents (www.biospace.com). After executing the $375 million buyback program, pro forma cash was roughly ~$318 million by late 2025 (www.biospace.com). Keros has no significant long-term debt – its debt-to-equity ratio was only ~0.06 in Q3 2025 (approximately $40–60 million debt vs $700 million equity) (www.macrotrends.net). Essentially, Keros is in a net cash position and does not rely on leverage to fund operations. Interest expense is negligible (net interest was only a few thousand dollars in recent periods) and the company in fact earns interest income on its cash, so interest coverage is not a concern. In terms of liquidity, Keros’s cash runway is ample: management estimates that the post-buyback cash on hand will fund operating expenses through the first half of 2028 without needing additional capital (www.biospace.com). This suggests no near-term financing or dilution risk barring unforeseen circumstances, providing a comfortable buffer to advance rinvatercept through Phase 2 trials and possibly into Phase 3. The company also significantly reduced its cost base in 2025 – it cut ~45% of its workforce amid a corporate restructuring (www.nasdaq.com) and shifted elritercept’s expenses to Takeda (www.biospace.com). These moves shrank quarterly R&D spend (Q3 2025 R&D was $19.5 M, down from $49.2 M in Q3 2024) (www.biospace.com). Cash burn is now more modest given the narrower pipeline, reinforcing the runway guidance. Overall, Keros’s financial health and coverage of obligations appear solid for a pre-revenue biotech: it has the cash to cover its planned R&D investments for several years and no looming debt maturities.
Valuation and Comps
Traditional valuation metrics like P/E or P/FFO are not meaningful for Keros since it has no earnings or funds from operations yet. Instead, investors value KROS based on its asset portfolio and cash. After the stock’s collapse in late 2024 (when the PAH trial setback erased ~$2 billion in market cap (www.biopharmadive.com)), Keros has been trading near its net asset value. As of early 2026, the stock sits around the high teens per share, roughly on par with book value (~$17–18 per share) (www.macrotrends.net). In mid-2025, at its trough, KROS traded at only ~0.8× book value (www.macrotrends.net), reflecting deep skepticism after the clinical failure. Even after a modest rebound, the current price-to-book ~1× implies the market is valuing Keros predominantly for its cash on hand, with little credit for pipeline upside. In other terms, Keros’s enterprise value (EV) is minimal – subtracting ~$300+ million in cash from its ~$350 million market cap leaves an EV on the order of only a few tens of millions. This suggests that Wall Street assigns a low probability of success (or low potential profitability) to Keros’s remaining pipeline at present. By comparison, high-profile gene therapy developers in DMD trade at hefty valuations based on anticipated future sales, whereas Keros’s muscle-enhancement approach is seen as highly speculative. If rinvatercept shows clinical efficacy, there could be substantial upside from this low base, as a DMD or ALS therapy could represent a multi-billion dollar market opportunity. However, until clinical proof-of-concept is achieved, KROS is likely to trade at a steep “risk discount” relative to peers. Investors considering comps might look at other muscle-directed therapy developers (e.g. companies targeting myostatin or related pathways) – notably, past attempts at myostatin inhibitors in DMD have failed to improve patient outcomes (pmc.ncbi.nlm.nih.gov), which may temper valuations for Keros. Overall, the current valuation prices in caution: KROS is valued almost like a sum-of-cash parts, with the pipeline essentially a free option in the eyes of the market.
Risks and Red Flags
Keros faces significant clinical and development risks. The company’s prior lead program, cibotercept for PAH, encountered serious safety issues (pericardial effusions) that forced a dosing halt (www.biopharmadive.com) and led to the program’s termination. This incident triggered a 77% crash in the stock and destroyed investor confidence (www.biopharmadive.com). Analysts at the time underscored that cibotercept had been Keros’s “lead program and main value driver,” and its setback made it “difficult to regain investor interest” (www.biopharmadive.com). This is a glaring red flag in Keros’s history – it highlights the binary risk of early-stage biotech R&D, where a single trial failure can wipe out most of the company’s value. Moving forward, rinvatercept now carries the weight of the company’s future, and it too is subject to high uncertainty. While Phase 1 data in healthy volunteers are encouraging mechanistically, there is no guarantee these translate to clinical benefits in DMD or ALS patients. Duchenne muscular dystrophy in particular has proven challenging for “muscle-building” therapies – multiple myostatin/activin inhibitors (e.g. Pfizer’s domagrozumab, Acceleron’s ACE-031) failed to show functional improvement in DMD (pmc.ncbi.nlm.nih.gov). Rinvatercept’s broad mechanism (blocking both myostatin and activin A) could yield better efficacy, but it remains unproven and will be tested in combination with standard DMD care (which now may include gene therapy or exon-skipping drugs). Regulatory and trial execution risks also loom: designing a Phase 2 DMD study with appropriate endpoints (muscle function, fibrosis markers, etc.) and recruiting patients in a competitive research space will be challenging. In ALS, demonstrating a meaningful clinical outcome (e.g. slowing progression) is equally difficult. Furthermore, Keros’s pipeline is now concentrated, offering less cushion if rinvatercept disappoints – the company no longer has a diversified portfolio after spinning off elritercept and ending cibotercept. Any unforeseen safety issue or lack of efficacy with rinvatercept would be devastating given this reliance on one asset.
Another risk pertains to strategic direction and governance. The events of 2025 – including the adoption of a short-term shareholder rights plan (ir.kerostx.com), activist involvement, and a massive buyback – indicate prior shareholder unrest. While the capital return appeased investors in the short run (www.globenewswire.com), it also saw the exit of prominent backers (ADAR1 and Pontifax sold their entire stakes) (www.globenewswire.com) (www.globenewswire.com). This could be interpreted as those informed investors cashing out, perhaps skeptical of Keros’s remaining prospects. The 45% workforce reduction in 2025, while financially prudent, raises concerns about whether Keros has sufficient personnel and resources to execute its clinical programs swiftly. There’s a fine line between “lean operations” and under-resourcing critical functions (trial management, regulatory, CMC, etc.). Keros will need to maintain operational excellence despite being a smaller organization. Finally, competition is a risk: for DMD, companies like Sarepta, Solid Biosciences, and others are developing gene therapies and novel approaches; even if rinvatercept works, its commercial uptake might depend on how it fits into a treatment paradigm rapidly evolving toward genetic medicines. For ALS, any new therapy would join a field littered with failures and where recent approvals (e.g. Relyvrio, tofersen) set a high bar for demonstrating benefit. Keros must also watch for any safety signals in long-term use, since systemic TGF-β pathway modulation could have off-target effects (though none significant were seen in Phase 1). In sum, the investment in KROS carries substantial risk: the company’s history has shown how quickly fortunes can reverse in biotech, and its future hinges on one early-stage program navigating both scientific and competitive challenges.
Open Questions and Outlook
Going forward, several key questions remain open for Keros: Can rinvatercept succeed where past muscle therapies have failed? The upcoming Phase 2 trials in DMD (and later ALS) will be crucial litmus tests. Investors will be watching for any early signs of clinical efficacy – for instance, improvements in muscle function or biomarkers in DMD patients – to validate rinvatercept’s mechanism. If positive, Keros’s fortunes could dramatically improve; if not, the company would need to rethink its strategy (with limited other shots on goal). How will Keros deploy its remaining cash? With an estimated ~$300 million in the bank, Keros theoretically has the means to fund Phase 2 studies and even a Phase 3 for DMD on its own (www.biospace.com). But given the size and complexity of a Phase 3 DMD trial, management might seek a partner or additional funding if Phase 2 data are promising. It’s also unclear whether Keros might in-license or acquire new programs to rebuild its pipeline diversification – so far, it appears committed to the neuromuscular focus, but future business development moves are possible once there’s clarity on rinvatercept’s prospects. Another question is whether further shareholder returns are on the table. The 2025 buybacks were a special case, enabled by the Takeda windfall; unless Keros receives large milestone payments (Takeda’s elritercept is entering Phase 3, which could trigger milestones), additional capital returns seem unlikely in the near term as the company will prioritize funding trials. Notably, Keros did commit to distribute a portion of any near-term Takeda milestone proceeds to investors (www.globenewswire.com) – one potential milestone could be if elritercept receives regulatory approvals down the line, though that is a few years off.
Keros’s long-term outlook hinges on clinical results. In a best-case scenario, by late 2026 or 2027 rinvatercept could show efficacy signals in DMD, which would not only de-risk the program but also open doors to strategic opportunities (e.g. a partnership with a larger pharma experienced in neuromuscular diseases, or even making Keros an acquisition target). Takeda’s deal validated Keros’s science in hematology; a success in DMD/ALS would validate it in muscle disease and might invite renewed interest from big pharma. Conversely, if results disappoint, Keros may face difficult decisions – potentially pivoting KER-065 to other indications (e.g. muscle wasting/cachexia), or leveraging its TGF-β expertise into new programs. Investors should also keep an eye on elritercept’s progress at Takeda. While Keros no longer develops it, positive Phase 3 results in MDS could result in milestone payments and royalties, providing non-dilutive capital and some upside (and conversely, setbacks there could forgo expected milestones).
In summary, KROS is at a pivotal juncture: the company has shored up its finances and slimmed down to focus on rinvatercept, which has shown promising early data at the MDA conference. The next 12–18 months will likely answer the critical question of whether that promise can translate into tangible clinical benefit for patients. Success in the DMD Phase 2 trial would be transformative for the stock’s valuation and narrative, whereas failure would leave Keros searching for a new path. With the stock trading near cash value and expectations low, the risk-reward profile is pronounced – KROS could be significantly re-rated on positive news, but it remains a high-risk bet reliant on unproven science. Investors should watch for trial initiations and interim updates from the Phase 2 studies as the next milestones. Until then, caution and patience are warranted, as the story of Keros Therapeutics will largely be written by the upcoming clinical data on rinvatercept.
Sources: Keros Therapeutics press releases and SEC filings (ir.kerostx.com) (ir.kerostx.com) (www.biospace.com); GlobeNewswire news (www.globenewswire.com) (www.globenewswire.com); BioPharma Dive (www.biopharmadive.com) (www.biopharmadive.com); Yahoo Finance (uk.finance.yahoo.com); Macrotrends and company financials (www.macrotrends.net); Pharmaphorum and industry reports (www.biopharmadive.com) (pmc.ncbi.nlm.nih.gov).
